The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

AgelessRx

Status: Completed

Conditions: Aging

Treatments: Drug: Rapamycin

Study type: Observational

Funder types: Industry

Identifiers

NCT06550271

ALRx005

Details and patient eligibility

About

This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Enrollment: 67 patients

Sex: All

Ages: 40 to 120 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Receive AgelessRx's standard Rapamycin treatment protocol
• Opted to complete at least 1 blood draw at their local Quest Lab

Exclusion criteria

• Not approved for current AgelessRx standard Rapamycin treatment
• History of uncontrolled disease
• Unable to complete at least 1 blood draw at their local Quest Lab

Trial design

67 participants in 2 patient groups

Compounded Rapamycin

Description:

Participants in this group were receiving Compounded Rapamycin (dosages include 5, 10, or 15mg) once per week

Treatment:

Drug: Rapamycin

Generic Rapamycin

Description:

Participants in this group were receiving Generia Rapamycin (dosages include 2,3,6, or 8mg) once per week

Treatment:

Drug: Rapamycin